WebZilretta (triamcinolone acetonide extended-release injectable suspension) is a non-opioid drug for managing chronic osteoarthritis (OA) knee pain. The previous label said Zilretta was "not intended for repeat administration." The new label states, "the efficacy and safety of repeat administration" of the drug "have not been demonstrated." WebDec 12, 2024 · Important Dosage and Administration Information. ZILRETTA is administered as a single intra-articular extended-release injection of triamcinolone acetonide, to deliver 32 mg (5 mL). ZILRETTA is for intra-articular use only and should not be administered by the following routes: epidural, intrathecal, intravenous, intraocular, intramuscular ...
Viscosupplementation - Medical Clinical Policy Bulletins
WebListing of a code in this policy does not imply that the service described by the code is a covered or non -covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. WebDec 1, 2024 · Zilretta Description. Zilretta (triamcinolone acetonide extended-release injectable suspension) is a microsphere formulation of triamcinolone acetonide, a corticosteroid, to be administered by intra-articular injection. Zilretta is formulated in 75:25 poly (lactic-co-glycolic acid) (PLGA) microspheres with a nominal drug load of 25% (w/w) … scattered tattoos women
Osteoarthritis of the Knee: Selected Treatments - Medical
WebPolicy. Aetna take arthroscopic debridement (with instead without partial meniscectomy) medically necessary for persons presenting with mild-to-moderate (Outerbridge classification I and II, not III or IV) osteoarthritis (OA) with knee pain extra mechanical symptoms due to detached bodies and/or meniscal tears. ... Zilretta Approved to Treat ... WebZILRETTA prescription and dosage sizes information for physicians and healthcare professionals. Pharmacology, adverse reactions, warnings and side effects. WebOct 1, 2024 · Zilretta 32 mg single-dose vial: 1 vial per knee ... McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. doi: 10.1016/j.joca.2014.01.003. Epub 2014 Jan 24. 6. Brown GA. AAOS clinical practice … scattered telangiectasias